ALDX Aldeyra Therapeutics Inc

$ALDX could be totally wrong but a webcast seems more bullish than a PR stating the meeting did not go well with FDA. Who knows

$ALDX Todd would never show his face if news was bad we all know that… I expect him to announce the next phase aka formal dispute filed for panel review like $OTLK

$ALDX their lawyers and the board chose to pursue a strategy which they know is flawed. i’ll put out a more comprehensive tweet. this appeal doesnt have any chance of achieving anything

$ALDX volume is much lighter today after that 4 million block yesterday. let me see over $1 tomorrow.

$ALDX I hope Todd was on the debate team in college. It’s going to take a performance of a life time to convince the FDA. I got 43k shares ridding on this guy. SMH!

$ALDX Is it really any wonder? Todd has been lying to us for years. Nothing he said was true.

$ALDX noted it will appeal the FDA's CRL for reproxalap and seek a dispute resolution, extending cash runway to 2029.

$ALDX I wonder how on tomorrow will go?🫣 I honestly don’t trust ALDX, but I have too much money into it to leave.

$ALDX Headed for $1.00 land imo... We got 2 overnight winners already need this one to go... Bounce time.. Ignore the posts that's have nothing to do with this stock.... This is a shame👇👇

$ALDX FDA is saying something like, this may work but it’s unclear for the group or use you want to claim. Tell us why failed studies failed so we can see if there’s an explanation. Tell us if there’s a group where is does clearly work. I’m long and I have to say, I understand the concerns. I think OND sides with past decision. The question would be, then, what now?

$ALDX Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease https://www.businesswire.com/news/home/20260929404066/en/Aldeyra-Therapeutics-Announces-Intent-to-Submit-Formal-Dispute-Resolution-Request-for-Reproxalap-to-Treat-Dry-Eye-Disease • Submission of the FDRR and a meeting with the OND are expected in the fourth quarter of 2026. ♦ The decision to submit the FDRR is based on the outcome of recent Type A and Type D meetings with the FDA. • Conference call this morning at 8:00am ET to discuss the FDRR.

$ALDX Aldeyra Therapeutics to Host Regulatory Update Webcast https://www.businesswire.com/news/home/20260928058014/en/Aldeyra-Therapeutics-to-Host-Regulatory-Update-Webcast ALDX will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00am ET. The update will focus on reproxalap, an investigational drug for the treatment of dry eye disease.

$ALDX this was just 1.44 few days ago.. this should move up into FDA catalyst. Funds into 2029.

$ALDX is moving on clinical trial results following a Business Wire release. Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease RTPR pushed this release out to users at 7:00:00 AM ET

$ALDX just a hello to the board- giess some old members are still here / evaluate vktx some know i m long therm there as i ve been here it looks promising and u might do some money back from here losses! Ciaoo

$ALDX If you pop up the 1 min chart there is zero volume to them sales under 15,000 shares traded since 2:30 est time

$ALDX Needs to see some insider buying to stop the bleed, CEO paid $1.67 on 400k shares so must be a bargain here right.

$ALDX see if insiders are buying here expect form 4s in the next few days that will stop the bleed.

$ALDX it was tute who went out in last 3 trading days. yesterday 4 million block. if that tute is completly gone then this goes back over $1.

$ALDX FYI - Legal Watch per ChatGPT-5: Stephen G. Machatha, PhD (former CDO ALDX, overseeing clinical trials) is now listed as Senior Vice President, Technical Operations at IMUNON, Inc., providing confirmation that he has secured a new executive role following his departure from Aldeyra. As you recall, he submitted his resignation to ALDX shortly after ALDX received written request from the FDA notifying a need for a PDUFA extension (March 16, 2026) to review ALL clinical trial data, back in December 2025.